Cryptogenic Stroke: Finding Light in the Darkness
|
|
|
- Barbra Jennifer Craig
- 5 years ago
- Views:
Transcription
1 Cryptogenic Stroke: Finding Light in the Darkness Scott E. Kasner, MD Professor of Neurology Director, Comprehensive Stroke Center
2 Disclosures WL Gore PI for Gore REDUCE Trial Medtronic DSMB for CRYSTAL AF Trial Bayer National Lead Investigator for NAVIGATE- ESUS Trial Boehringer Ingelhim Global Advisory Committee
3 Ischemic Stroke Subtypes Large Artery Small Vessel Cardioembolism Other Cryptogenic NINCDS Stroke Data Bank: Foulkes et al. Stroke. 1988;19:547. German Stroke Data Bank Grau A.J. et al. Stroke 2001;32:
4 Large Artery Atherothromboembolism 50% stenosis of a major extraor intracranial artery
5 Small Vessel (Lacunar) Stroke TOAST <1.5 cm; CCS <2.0 cm diameter
6 High Risk Sources of Cardioembolism Mechanical prosthetic valve Atrial fibrillation Intracardiac thrombus Dilated cardiomyopathy Recent myocardial infarction (<4 weeks) Akinetic left ventricular segment Atrial myxoma or fibroelastoma Infective endocarditis
7 Secondary Prevention of Ischemic Stroke What is the cause of the initial cerebrovascular event? Large vessel athero Cardioembolism Small vessel dz Revascularization Antiplatelet agent Anticoagulation Antiplatelet agent Risk factor modification Statin Lifestyle modification
8 Other Determined Causes Drugs Cocaine Amphetamines Infections Syphilis TB VZV Genetic disorders MELAS CADASIL Vasculopathy Dissection Vasculitis Vasoconstriction Prothrombotic disorders Factor deficiencies Anti-phospholipid Ab Sickle cell disease
9 Secondary Prevention of Ischemic Stroke What is the cause of the initial cerebrovascular event? Other Specific therapy for specific etiology
10 Ischemic Stroke Subtypes 30-40% Large Artery Small Vessel Cardioembolism Other Cryptogenic NINCDS Stroke Data Bank: Foulkes et al. Stroke. 1988;19:547. German Stroke Data Bank
11 Cryptogenic Stroke Where do they come from?
12 Secondary Prevention of Ischemic Stroke What is the cause of the initial cerebrovascular event? Cryptogenic?
13 What is Cryptogenic Stroke? Insufficient evaluation Thorough but negative evaluation Multiple competing causes Leftovers from the known cause categories that don t quite fit
14 Etiology? 68-year-old man with mild left face and arm weakness and mild neglect Risk factors: hypertension, prior smoker Neuroimaging: small right cortical infarction Carotid ultrasound: no significant stenosis EKG: sinus rhythm, normal Echo (transthoracic): EF 50%, no major wall motion abnormalities, normal valves, no source Labs: LDL 95, A1c 5.0%
15 How Thorough is Thorough? History and examination Carotid ultrasound EKG Telemetry in hospital Echocardiogram Routine blood tests
16 Insufficient Evaluation vs. Thorough But Negative Evaluation How thorough is thorough? Intracranial vascular imaging Transesophageal echo Prolonged cardiac telemetry Prothrombotic testing Weird stuff?
17 Cryptogenic Stroke: Why should we look for intracranial stenosis?
18 0.4 Probability of Stroke / Vascular Death Aspirin Warfarin Years after Enrollment
19 Beyond Medical Therapy
20 Intracranial Stenosis-Why Look? Prognosis High short term risk Medical Treatment (SAMMPRIS) Aspirin plus clopidogrel x 90 days Aggressive lipid and BP lowering Angioplasty/stent Definitely not first line approach
21 What are we really going to find on TEE? Aortic Arch Atheroma
22 What are we really going to find on TEE? Aortic Arch Atheroma
23 ARCH Trial warfarin asa/clopidogrel Recurrent event: 7.6% ASA/clop vs. 11.3% warfarin OR 0.76 ( ), p=0.50 Inconclusive
24 Cryptogenic Stroke: Are We Missing Paroxysmal Atrial Fibrillation? Biological and genetic plausibility Detection of asymptomatic / occult AF Diagnostic dilemma
25 AF: Symptoms and Stroke 50-90% AF episodes are asymptomatic Even in patients with symptoms, ratio of asymptomatic to symptomatic is 12:1 25% of those with AFassociated stroke have no known history of AF Even in stroke patients with known PAF, 50-70% present in sinus rhythm
26 Mobile Cardiact Outpatient Telemetry (MCOT) in Cryptogenic Stroke (N=56) Tayal et al. Neurology 2008;71:
27 AF detected day 21
28 Time to Detection of New Dx of AF Telemetry in hospital Holter monitor Prolonged monitoring Freedom from AT/AF % of NDAF patients identified beyond 1 day 78% of NDAF patients identified beyond 7 days 60% of NDAF patients identified beyond 30 days mo. 6 mo. 9 mo. 12 mo. Number at Risk: Time from Device Implant (months) Ziegler et al. Stroke 2010;41:
29 AF detection after stroke
30 Cryptogenic Stroke and Underlying Atrial Fibrillation (CRYSTAL AF) Trial 450 cryptogenic stroke patients Randomized to Reveal XT implantation vs. routine care Primary end point was time to detection of AF within 6 months after stroke
31
32 CRYSTAL AF Study More AF with longer monitoring 6 months: 8.9% vs. 1.4% 12 months: 12.4% vs. 2% 36 months: 30% vs. 3% 92% of Afib events were >6 minutes 2.4% of patients required device explantation
33 Implantable Monitors Implanted under skin Records up to 3 years
34 Look Harder for Occult AFib ~20% of cryptogenic stroke pts have occult AF Most AF episodes are asymptomatic AF yield increased with longer monitoring duration Unknown optimal duration (forever?) Short AF episodes of uncertain significance Treatment options for AFib expanding every day
35 How much AF increases risk of stroke?
36 Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES Thomas Vanassche1*, Mandy N. Lauw1, John W. Eikelboom1, Jeff S. Healey1, Robert G. Hart1, Marco Alings2, Alvaro Avezum3, Rafael Dı az4, Stefan H. Hohnloser5, Basil S. Lewis6, Olga Shestakovska1, JiaWang1, and Stuart J. Connolly1
37 Meta-analysis of DOAC Trials
38 2580 patients >65 years with recent pacemaker or AICD Subclinical atrial tachyarrhythmias (>6 minutes) were detected in 10.1% by 3 months, with more over time Subclinical atrial tachyarrhythmias independently associated with ischemic stroke or systemic embolism HR 2.5; 95% CI: ; p=0.008 Atrial fibrillation vs. atrial something? Healey, JS et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med 2012;366:
39 Detecting subclinical AF in pacemaker patients without history of AF Cumulative incidence SCAF >6mins SCAF >6hours SCAF >24hours Brief AF ~5x more common than AF>24hr No. at Risk SCAF >6mins SCAF >6hours SCAF >24hours Years of Follow-up Unpublished from ASSERT
40 Risk of ischemic stroke or systemic embolism according to duration of SCAF Cumulative event rates No SCAF 6mins~6hrs 6hrs~24hrs >24hrs Only AF>24h associated with future stroke risk!!! Years of Follow-up No. at Risk No SCAF mins~6hrs hrs~24hrs >24hrs Unpublished from ASSERT
41 What is Cryptogenic Stroke? Insufficient evaluation Thorough but negative evaluation Multiple competing causes Leftovers from the known cause categories that don t quite fit
42 Cryptogenic Stroke: Carotids negative 40% stenosis
43 Are These Lacunar Strokes? TOAST <1.5 cm; CCS <2.0 cm diameter
44 Medium Risk Sources of Cardioembolism Mitral valve prolapse Mitral annulus calcification Mitral stenosis Atrial septal aneurysm Patent foramen ovale Congestive heart failure Atrial flutter Left atrial turbulence (smoke) Bioprosthetic cardiac valve Nonbacterial thrombotic endocarditis Hypokinetic left ventricular segment Myocardial infarction (>4 weeks, <6 months)
45 Patent Foramen Ovale (PFO) Congenital cardiac anomaly in ~25% people Fibrous adhesions fail to seal the atrial septum
46 One year follow-up 3D Echocardiogram Courtesy of John Rhodes, MD
47 PFO Closure Trials Meta-Analysis
48 Gore REDUCE Study 664 patients with cryptogenic stroke and PFO Exclude arterial stenosis, cardioembolism, lacunes, hypercoag Randomized to device closure versus antiplatelet therapy At least 2 years of clinical follow-up Primary outcome: stroke MRI confirmation of baseline stroke MRI of all suspected events MRI at 2 years (for subclinical infarctions) Multinational trial Results in Spring 2017!!!!
49 What is Cryptogenic Stroke? Insufficient evaluation Look harder! Thorough but negative evaluation Are you sure it is negative? Leftovers from the known cause categories that don t quite fit Should we make them fit? Multiple competing causes Are these really cryptogenic?
50 Ischemic Stroke Subtypes 30-40% Large Artery Small Vessel Cardioembolism Other Cryptogenic
51 Ischemic Stroke Subtypes Improved Diagnosis and Definition <10% Large Artery Small Vessel Cardioembolism Other Cryptogenic
52 Embolic Stroke of Uncertain Source (ESUS) Stroke detected by CT or MRI that is not lacunar Subcortical infarct 1.5 cm ( 2.0 cm on DWI) in largest dimension, and in the distribution of the small, penetrating cerebral arteries. Absence of extracranial or intracranial atherosclerosis Causing a 50% luminal stenosis in arteries supplying the area of ischemia No major-risk cardioembolic source of embolism AF, intracardiac thrombus, prosthetic valve, myxoma/tumors, mitral stenosis, recent MI, EF<30%, vegetations No other specific cause of stroke identified (e.g., arteritis, dissection, migraine/vasospasm, drug misuse) Lancet 2014
53 ESUS Components Truly unexplained ischemic stroke Stroke with undetected/occult AF or atrial something Stroke due to low-to-medium risk cardiac sources Stroke due to arch atheroma Stroke due to <50% extra- or intracranial atherosclerosis And many others yet to be determined
54 Secondary Prevention of Ischemic Stroke What is the cause of the initial cerebrovascular event? Cryptogenic/ ESUS?
55 Cryptogenic Stroke Maybe we should just shoot first and ask questions later!
56 Anticoagulation For ESUS? Post hoc subgroups from WARSS Sacco, 2006
57 Anticoagulation For ESUS? Intracranial stenosis (WASID) Aortic arch atheroma (ARCH)
58 Anticoagulation for ESUS? PFO (RESPECT)
59 AVERROES: Apixaban Better than Aspirin for AF Stroke or Systemic Embolism Cumulative Risk RR= %CI= p<0.001 ASA Apixaban Months No. at Risk ASA Apix
60 Apixaban: Similar Risk of Major Bleeding as Aspirin 5 Major bleeding (%) Aspirin Apixaban Compared to aspirin: Apixaban: 1.14 ( ); p=0.56
61 Anticoagulation vs. Aspirin? Trials underway: NAVIGATE-ESUS Rivaroxaban vs. aspirin for allesus RESPECT-ESUS Dabigatran vs. aspirin for all ESUS ARCADIA (soon) Apixaban vs. aspirin for ESUS with atrial cardiopathy
62 Cardiac monitors TEE Xa inhibitors Vascular imaging DTIs
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.
True cryptogenic stroke
True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures
Management and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
How Can We Properly Manage Patients With Stroke of Undetermined Origin?
How Can We Properly Manage Patients With Stroke of Undetermined Origin? : Spotlight on Embolic Stroke of Undetermined Source (ESUS) MI SUN OH Department of Neurology, Hallym University Scared Heart Hospital,
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
Stroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow
Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia
Cryptogenic Strokes: Evaluation and Management
Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the
Speakers. 2015, American Heart Association 1
Speakers Lee Schwamm, MD, FAHA Executive Vice Chairman of Neurology, Massachusetts General Hospital Director, Stroke Service and Medical Director, MGH TeleHealth, Massachusetts General Hospital Director,
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
Defining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]
![[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]](/thumbs/89/98619893.jpg "[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]")
2015 PHYSICIAN SIGN-OFF (1) STUDY NO (PHY-1) CASE, PER PHYSICIAN REVIEW 1=yes 2=no [strictly meets case definition] (PHY-1a) CASE, IN PHYSICIAN S OPINION 1=yes 2=no (PHY-2) (PHY-3) [based on all available
Non-commercial use only
Italian Journal of Medicine 2016; volume 10:202-206 Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit Marco Masina, 1 Annalena Cicognani, 1 Carla Lofiego, 2 Simona
ACUTE CENTRAL PERIFERALEMBOLISM
EAE TEACHING COURSE 2010 Belgrade, Serbia October 22-23, 2010 ACUTE CENTRAL and PERIFERALEMBOLISM Maria João Andrade Lisbon, PT BACKGROUND Stroke is a leading cause of mortality and long-term disability
Subclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
Stroke Update. Claire J. Creutzfeldt, MD January 12, 2018
Stroke Update Claire J. Creutzfeldt, MD January 12, 2018 Disclosures None relevant to this presentation I receive funding from the NINDS What s new in stroke? A new model for cardioembolic stroke: atrial
PFO Management update
PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
Cryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
DIFFERENT STROKES FOR DIFFERENT FOLKS!!
DIFFERENT STROKES FOR DIFFERENT FOLKS!! Identifying Stroke Subtypes SWAROOP PAWAR M.D., MPH. Vascular Neurologist UMG Neuroscience Associates Greenville Health System None Disclosures Outline Stroke, TIA
Cryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
Permanent foramen ovale: when to close?
Permanent foramen ovale: when to close? Pierre Amarenco INSERM U-698 and Denis Diderot University - Paris VII Department of Neurology and Stroke Center Bichat hospital, Paris, France PFO - Pathology TEE
CEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
Alan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with Non-fluent dysphasia R facial weakness Background Ischaemic heart disease Hypertension Hyperlipidemia L MCA branch
Embolinen aivoinfarkti vailla
Embolinen aivoinfarkti vailla syytä (ESUS) Neurologipäivät 2.11.2017 Jukka Putaala, vsel HYKS 1 Disclosures Research grant Helsinki and Uusimaa Hospital District, Academy of Finland, Finnish Funding Agency
Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology
Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology Ann M. Leonhardt Caprio, MS, RN, ANP-BC Program Coordinator Comprehensive Stroke Center, Strong Memorial Hospital Clinical
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο
Karl Meisel, MD MA Director of Stroke Clinic University of California San Francisco
Karl Meisel, MD MA Director of Stroke Clinic University of California San Francisco I have no financial disclosures 1 Hospital Management Thrombolytic and Thrombectomy Blood pressure Stroke in the Young
GERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
Sixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist
W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist 1 One Strategy for cryptogenic stroke: ESUS Positively defined criteria FDA allows clinical trials NOACs have lower risk profile Another strategy
I, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
Embolic Stroke of Undetermined Source (ESUS) Lee Birnbaum, MD, MS Depts of Neurology and Neurosurgery UTHSCSA
Embolic Stroke of Undetermined Source (ESUS) Lee Birnbaum, MD, MS Depts of Neurology and Neurosurgery UTHSCSA Disclosures UTHSCSA Site-PI for NAVIGATE ESUS Industry sponsored by Bayer New Approach rivaroxaban
When Should I Order a Stress Test or an Echocardiogram
When Should I Order a Stress Test or an Echocardiogram Updates in Cardiology 2015 March 7, 2015 Donald L. Lappé, MD, FAHA, FACC Chairman, Cardiovascular Department Medical Director, Intermountain Cardiovascular
Secondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
Alan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with L numbness & slurred speech 2 episodes; 10 mins & 2 hrs Hypertension Type II DM Examination pulse 80/min reg, BP 160/95
DOAC: future possibili indicazioni
DOAC: future possibili indicazioni (IMA, stroke criptogenico, TVC, TV viscerali) Alberto Tosetto UOS Centro Malattie Emorragiche e Trombotiche Divisione di Ematologia, Ospedale S. Bortolo AULSS 8 Berica,
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
Supplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hart RG, Diener H-C, Coutts SB, et al,
NIH Public Access Author Manuscript J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2008 September 1.
NIH Public Access Author Manuscript Published in final edited form as: J Stroke Cerebrovasc Dis. 2007 ; 16(5): 216 219. Echocardiography in Patients with Symptomatic Intracranial Stenosis Scott E. Kasner,
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
MEET 2007: Evaluation and treatment of the stroke and TIA patient for the non-neurointerventionist. neurointerventionist
MEET 2007: Evaluation and treatment of the stroke and TIA patient for the non-neurointerventionist neurointerventionist Steve Ramee, MD Ochsner Medical Center New Orleans DISCLOSURE Nothing Nothing to
Asif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
/ / / / / / Hospital Abstraction: Stroke/TIA. Participant ID: Hospital Code: Multi-Ethnic Study of Atherosclerosis
Multi-Ethnic Study of Atherosclerosis Participant ID: Hospital Code: Hospital Abstraction: Stroke/TIA History and Hospital Record 1. Was the participant hospitalized as an immediate consequence of this
Patent foramen ovale (PFO) is composed of
PFO Closure for Prevention of Recurrent Cryptogenic Stroke The evidence base is here. BY JOHN F. RHODES, JR, MD Patent foramen ovale (PFO) is composed of overlapping portions of septum primum and septum
A Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring
SAGE-Hindawi Access to Research Stroke Research and Treatment Volume 2011, Article ID 172074, 5 pages doi:10.4061/2011/172074 Clinical Study Predictors of Occult Paroxysmal Atrial Fibrillation in Strokes
Slide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure
Slide 1 The Treatment of Intracranial Stenosis Helmi Lutsep, MD Vice Chair and Dixon Term Professor, Department of Neurology, Oregon Health & Science University Chief of Neurology, VA Portland Health Care
FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M.
FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M. Bufalini - Cesena FORAME OVALE PERVIO ICTUS CRIPTOGENETICO FORAME OVALE PERVIO
Is Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
Antithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
Detailed Order Request Checklists for Cardiology
Next Generation Solutions Detailed Order Request Checklists for Cardiology 8600 West Bryn Mawr Avenue South Tower Suite 800 Chicago, IL 60631 www.aimspecialtyhealth.com Appropriate.Safe.Affordable 2018
CLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence
CLOSE Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence Guillaume TURC, MD, PhD Paris Descartes University Sainte-Anne hospital Paris, France On
Direct Oral Anticoagulants Beyond Atrial Fibrillation and Venous thrombosis
Direct Oral Anticoagulants Beyond Atrial Fibrillation and Venous thrombosis Robert D. McBane II Gonda Vascular Center 2018 MFMER 3755772-1 Disclosures Bristol-Myers Squibb Research Grant Apixaban in Cancer
MD SUBTYPE ADJUDICATION VARIABLE DEFINITIONS MANUAL The following is a list of variables and how to complete each one:
MD SUBTYPE ADJUDICATION VARIABLE DEFINITIONS MANUAL 2014-15 The following is a list of variables and how to complete each one: (PHY-1) Case, per physician review: The most important task for the physicians
How to Evaluate Patients with Cryptogenic Stroke
How to Evaluate Patients with Cryptogenic Stroke Jeffrey Saver, MD Professor of Neurology Director, How to Evaluate Patients with Cryptogenic Stroke Disclosure Scientific Consultant, Unpaid Trialist: AGA
Primary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough
Todd W GenslerMD April 28, 2018 CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough DISCLOSURES I have no financial disclosures Presenter name
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
APPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
TIA: Updates and Management 2008
TIA: Updates and Management 2008 S. Andrew Josephson, MD Department of Neurology, Neurovascular Division University of California San Francisco Commonly Held TIA Misconceptions TIA is easy to diagnose
Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know. Case 1 4/5/11. What treatment should you initiate?
Advances in Prevention and Treatment of Stroke: What Every Primary Care Physician Needs to Know S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University
Atrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation
The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
Modena, 6 novembre Heart and Brain. Paolo Bovi
MODENA STROKE CONGRESS 2014 Modena, 6 novembre 2014 Heart and Brain Paolo Bovi Stroke Unit UO Neurologia A DAI di Neuroscienze Azienda Ospedaliera Universitaria Integrata Verona I do not say so, but at
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
2015 Update in Diagnosis and Management of Stroke
2015 Update in Diagnosis and Management of Stroke S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Senior Executive Vice Chair, Department
Why Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
2018 Update in Diagnosis and Management of Stroke
2018 Update in Diagnosis and Management of Stroke S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Chair, Department of Neurology Director,
Adult Echocardiography Examination Content Outline
Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
Symptoms of small vessel strokes. Small Vessel stroke. What is this? Treatment. Large Vessel stroke 6/1/2018
Stroke Stroke Megan Stevens MD Vascular Neurology SUDDEN Maximal at onset Lateralized weakness, lateralized numbness, vision loss (one eye or portion of field in both eyes), double vision, slurred speech,
Stroke Topics. Advances in the Prevention and Treatment of Stroke. Non-Contrast Head CT. Patient 1-68 yo man
Stroke Topics Advances in the Prevention and Treatment of Stroke August 10, 2009 John W. Engstrom, M.D. Professor of Neurology Acute treatment options for ischemic stroke tpa, clot retraction, future directions
Long-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
Patent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
Ictus ischemico ed emorragico. Maurizio Paciaroni Stroke Unit University of Perugia
Ictus ischemico ed emorragico Maurizio Paciaroni Stroke Unit University of Perugia DISCLOSURES Maurizio Paciaroni has participated over the last 5 years for the following speakers bureaus: - Aspen - Bayer
Review Article Antithrombotic Medication for Cardioembolic Stroke Prevention
SAGE-Hindawi Access to Research Stroke Research and Treatment Volume 2011, Article ID 607852, 23 pages doi:10.4061/2011/607852 Review Article Antithrombotic Medication for Cardioembolic Stroke Prevention
Conflict Disclosures. Vermont Cardiac Network. Outline. Series Learning Objectives 4/27/2016. Scott E. Friedman April 28, 2016
Conflict Disclosures Vermont Cardiac Network The Speaker has reported no significant financial relationship with any companies whose product may be germane to the content of their presentations or who
Secondary Prevention of. Stroke: What a GP needs to know
Secondary Prevention of P. O Mahony Consultant Stroke Physician St Helier Hospital, Surrey S. Howie V. Jones Stroke: What a GP needs to know Correspondence: P. O Mahony Stroke Department, St Helier Hospital,
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Cardiac Issues
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Cardiac Issues Wein T, Gladstone D (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2017 Heart and Stroke Foundation September 2017
An international, double-blind, phase III randomized trial. Main Results
An international, double-blind, phase III randomized trial Main Results Robert Hart on behalf of the NAVIGATE ESUS Steering Committee and Investigators Sponsorship & Disclosures NAVIGATE ESUS was sponsored
Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
CLINICAL FEATURES THAT SUPPORT ATHEROSCLEROTIC STROKE 1. cerebral cortical impairment (aphasia, neglect, restricted motor involvement, etc.) or brain stem or cerebellar dysfunction 2. lacunar clinical
Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale?
ORIGINAL ARTICLE Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale? Masahiro YASAKA, Ryoichi OTSUBO, Hiroshi OE and Kazuo MINEMATSU Abstract Objective Purpose was to assess the stroke
Disclosures. CREST Trial: Summary. Lecture Outline 4/16/2015. Cervical Atherosclerotic Disease
Disclosures Your Patient Has Carotid Bulb Stenosis and a Tandem Intracranial Stenosis: How Do SAMMPRIS and Other Evidence Inform Your Treatment? UCSF Vascular Symposium 2015 Steven W. Hetts, MD Associate
Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
NeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
Qualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect
Qualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect JEFFREY L. SAVER, MD DAVID E. THALER, MD, PHD, RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT
Update in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
Antithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran: